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Abstract:
Hemophagocytic lymphohistiocytosis (HLH) represents a severe hyperinflammatory condition with cardinal symptoms 
of prolonged fever, cytopenias, hepatosplenomegaly, and hemophagocytosis by activated, morphologically benign 
macrophages with impaired function of natural killer cells and cytotoxic T lymphocytes. A 2-month-old girl, who was 
admitted with fever, was diagnosed with HLH and her genetic examination revealed a newly defined mutation in the 
UNC13D (c.175G>C; p.Ala59Pro) gene. She was treated with dexamethasone, etoposide, and intrathecal methotrexate. 
During the second week of treatment, after three doses of etoposide, it was noticed that there was a necrotic plaque 
lesion on the soft palate. Pathologic examination of debrided material in PAS and Grocott staining revealed lots 
of septated hyphae, which was consistent with aspergillosis infection. Etoposide was stopped and amphotericin B 
treatment was given for six weeks. HLH 2004 protocol was completed to eight weeks with cyclosporine A orally. There 
was no patient with invasive aspergillosis infection as severe as causing palate and nasal septum perforation during 
HLH therapy. In immuncompromised patients, fungal infections may cause nasal septum perforation and treatment 
could be achieved by antifungal therapy and debridement of necrotic tissue.
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Öz:
Hemofagositik lenfohistiositoz (HLH) uzamış ateş, sitopeni, hepatosplenomegali semptomları ile seyreden, active 
olmuş, morfolojik olarak benign makrofaj ve doğal öldürücü hücreler ile sitotosik T lenfosit fonksiyon bozukluğu 
sonucu gelişen hiperenflamatuvar bir durumdur. İki aylık düşmeyen ateş yakınması ile başvuran hasta HLH tanısı aldı 
ve hastanın genetik incelemesinde UNC13D (c.175G>C; p.Ala59Pro) geninde yeni tanımlanan bir mutasyon saptandı. 
Hastaya deksamatazon, etopozit ve intratekal metotreksat tedavileri başlandı. Tedavinin 2. haftasında, üç doz etopozit 
aldıktan sonra, yumuşak damakta plak lezyonu fark edildi ve bu nekrotik lezyon debride edildi. Debridman 
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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a severe 
life-threatening disease precipitated by secretion of cytokines 
from morphologically benign macrophages, which ends 
with uncontrolled hyperinflammation with prolonged fever, 
cytopenias, hepatosplenomegaly, and hemophagocytosis. 
Elevation of triglycerides, ferritin, lactate dehydrogenase, 
and transaminase levels and decreases in fibrinogen levels are 
characteristic findings [1]. Impaired cytotoxic function of T 
cells and natural killer cells is a known cause of familial forms 
of HLH. The HLH-2004 protocol with immunomodulatory 
and cytotoxic drugs is used for treatment of patients with HLH 
[2]. Importantly, invasive infections have been reported in up 
to 56% of children with HLH on chemotherapy, with invasive 
fungal infections causing 50% of deaths among such cases [3].
Here we report an unusual aspergillosis infection with 
palate and nasal septum perforation following chemotherapy 
in a patient with familial HLH with a novel mutation in 
UNC13D. Notably, the fungal infection in our patient was 
treated successfully with antifungal therapy and surgical 
debridement. 
Case Presentation
A 2-month-old girl, born subsequent to a term gestation 
with unrelated parents and an unremarkable previous history, 
was referred to our clinic with unremitting fever since 1 month 
despite repeated intravenous administrations of antibiotics. 
There was no history of sibling death in her family. On 
admission, vital signs were normal except body temperature 
of 38.7 °C. The patient was pale with petechial rashes on the 
lower extremities. She displayed hepatomegaly (6 cm below 
costal margin) and splenomegaly (3 cm below costal margin). 
Informed consent was obtained.
The patient’s laboratory findings were as follows; 
hemoglobin: 63 g/L, mean corpuscular volume (MCV): 88.9 
fL, total leukocyte count: 2.84x109/L, thrombocyte count: 
10x109/L, alanine aminotransferase (ALT): 50 IU/L, aspartate 
aminotransferase (AST): 62 IU/L, total bilirubin: 0.58 mg/
dL, direct bilirubin: 0.7 mg/dL, gamma glutamyl transferase: 
328 U/L, albumin: 2.9 g/dL, ferritin: 2000 ng/mL, triglyceride: 
617 mg/dL, LDL cholesterol: 11 mg/dL, HDL cholesterol: 7 
mg/dL, lactate dehydrogenase: 379 U/L, uric acid: 2.3 mg/dL, 
fibrinogen: 107 mg/dL. Her renal function tests and electrolytes 
were normal. Her peripheral smear revealed 4% neutrophils, 
90% lymphocytes, and 6% monocytes. Absolute neutrophil 
count was 0.113x109/L. No hemolysis or blasts were visible in 
her peripheral blood smear. Her transaminase levels increased 
on the third day of administration (AST: 280 IU/L, ALT: 265 
IU/L). Serological studies for infection with Epstein-Barr 
virus, parvovirus B19, cytomegalovirus, Toxoplasma gondii, 
rubella, Leishmania, and hepatitis were all negative. Natural 
killer cell activity and soluble IL-2 level could not be analyzed. 
Numerous histiocytes showing hemophagocytosis were 
observed in the bone marrow aspiration smears. 
Conclusively, the patient fulfilled a required 5 out of 6 
examined diagnostic criteria for the diagnosis of HLH [1]. 
Accordingly, the patient was treated with the HLH-2004 
protocol with dexamethasone, etoposide, and cyclosporine 
A. Mutation analyses, identifying a novel homozygous variant 
in UNC13D (c.175G>C; p.Ala59Pro), confirmed a diagnosis 
of familial HLH. The variant was not found in the healthy 
population (1000 Genomes database), and it was predicted as 
possibly damaging by PolyPhen-2 but as tolerated by sorting 
tolerant from intolerant (SIFT). The father was a heterozygous 
carrier of the mutation, while the mother could not be tested. 
During the second week of treatment, after 3 doses of 
etoposide at 150 mg/m2/dose, a grossly necrotic soft tissue 
lesion was noticed on the soft palate and was successfully 
excised (Figure 1). During the operation an oronasal fistula 
was revealed, as well as a perforation of the caudal side of 
the nasal septum along with an abscess formation in the left 
vestibular floor. Although there was no microbial growth 
in the necrotic material, microscopic examination of the 
debrided material in PAS and Grocott staining showed 
abundant septatedhyphae, consistent with aspergillosis 
infection (Figure 2). Etoposide was stopped and amphotericin 
B treatment was given for 6 weeks at a dosage of 3.5 mg/kg/
day. The HLH-2004 protocol was followed for 8 weeks with 
cyclosporine A and dexamethasone orally. 
Işık Balcı Y, et al: Invasive Aspergillosis in HLH with Novel UNCD13 Mutation
materyalinin patolojik incelemesinin PAS, Grocott boyamasında aspergilloz enfeksiyonu ile uyumlu olarak çok sayıda 
septalı hif görüldü. Etopozid tedavisi sonlandırılarak altı hafta boyunca amphotericin B tedavisi verildi. HLH 2004 
tedavi protokolü oral siklosporin ile sekiz haftaya tamamlandı. HLH tedavisi sırasında yumuşak damak perforasyonuna 
neden olacak kadar ağır aspergilloz enfeksiyonu geçiren bir olgu bildirilmemiştir. İmmünyetmezlikli hastada mantar 
enfeksiyonları nazal septum perforasyonuna neden olabilmektedir ve tedavi nekrotik dokunun debridmanı ve antifungal 
tedavi ile sağlanabilmektedir.
Anahtar Sözcükler: Hemofagositik lenfohistiositoz, İnvaziv aspergilloz enfeksiyonu, UNC13D (c.175G>C; 
p.Ala59Pro)
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At the most recent follow-up, after 4 months, the patient 
still presented with a 2-cm hepatosplenomegaly, while her 
soft palate had successfully epithelialized. However, there is a 
permanent deformity of her nose. Her laboratory findings were 
as follows; hemoglobin: 103 g/L, MCV: 77.7 fL, total leukocyte 
count: 15,280x109/L, thrombocytes: 230,000x109/L, ALT: 
32 IU/L, AST: 12 IU/L, ferritin: 916 ng/mL, triglyceride: 421 
mg/dL, LDL cholesterol: 78 mg/dL, HDL cholesterol: 20 mg/
dL, lactate dehydrogenase: 226 U/L, uric acid: 1.7 mg/dL, 
fibrinogen: 233 mg/dL. Until bone marrow transplantation 
she was treated with oral cyclosporine A (at the HLH-2004 
protocol dosage), trimethoprim sulfamethoxazole, and 
fluconazole. 
Discussion and Review of the Literature 
Herein we describe the disease course of a patient carrying 
a novel homozygous UNC13D mutation. Familial HLH cases 
typically have an earlier presentation, with infectious agents 
including herpes viruses such as the Epstein-Barr virus 
precipitating disease. However, in our case, we did not detect an 
infectious etiological agent. For treatment, chemoimmunotherapy 
(etoposide, dexamethasone, cyclosporine A, and, for selected 
patients, intrathecal methotrexate or corticosteroids) is 
recommended, but for severe disease or familial cases hemopoietic 
stem cell transplantation is life saving [4].
Opportunistic infections are a common complication of 
immunosuppression caused by cytotoxic treatment of the disease 
and by the disease itself. As our case illustrates, HLH patients 
have a potential risk of developing invasive fungal infections that 
can be severe. Aspergillus species have emerged as an important 
cause of life-threatening infections in immunocompromised 
patients. Highlighting the severity of invasive fungal infections, 
6/12 (50%) fatal cases in a study cohort of 18 children with 
primary HLH were reported to be caused by invasive fungal 
infections, of which 2 cases were diagnosed with invasive 
Aspergillus infection first at autopsy [5].
Aspergillus can differentiate into hyphal forms that 
produce toxins damaging epithelial tissue, leading to invasion 
of connective and vascular tissue by the fungi, which 
subsequently can result in thrombosis and ultimately necrosis 
of hard and soft tissues with perforation. Systemic antifungal 
therapy and surgical resection or debridement is important 
for the management of invasive sinonasalaspergillosis. 
Amphotericin B, voriconazole, and caspofungincan be 
considered for antifungal therapy [5]. Our case was treated 
successfully with surgical debridement and 6 weeks of 
amphotericin B treatment. 
In the English literature, the case of a 15-year-old boy 
who developed fungal infection with nasal septal perforation 
after bone marrow transplantation for acute myeloid leukemia 
was reported. He was also treated successfully with surgical 
debridement and amphotericin B [6].
Our report represents an interesting case of familial 
HLH caused by a novel homozygous UNC13D mutation and 
affected by invasive sinonasal aspergillosis. 
The UNC13D gene encodes for the Munc13-4 protein, a 
critical effector of the exocytosis of cytotoxic granules priming 
cytotoxic granule fusion. Munc13-4 deficiency impairs the 
delivery of the effector proteins, perforin and granzymes, into the 
target cells, resulting in defective cellular cytotoxicity and a 
clinical picture that appears very similar to that of FHL-2 [7]. 
UNC13D mutations are present in almost 30%-40% of familial 
HLH cases [8].
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Figure 1. Partial perforation in septal cartilage.
Figure 2. Septated hyphae with 45° angle branching in 
aspergillosis (Grocott, 100x).
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To the best of our knowledge, no c.175G>C; p.Ala59Pro 
mutation in UNC13D has been presented before in the 
literature. This novel mutation may be responsible for our 
patient’s severe clinical condition. However, to compare the 
mutation type and clinical course, there is a need for clinical 
studies. 
We want to emphasize the importance of awareness of 
the occurrence of potentially life-threatening invasive fungal 
infections in patients with HLH. Furthermore, this highlights 
the efficacy of surgical debridement and amphotericin B for 
successful treatment of fungal infections with focal lesions.
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